Señales en vivo de ONCT | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (2 may 2024 @ 16:00):

Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs...

Stats
Volumen de hoy	72.00
Volumen promedio	7 769.00
Capitalización de mercado	25.88M
EPS	$0 ( 2024-05-02 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.650
ATR14	$0.151 (1.73%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-08	Wills Robert James	Buy	3 086	Common Stock
2024-03-28	Wills Robert James	Buy	6 914	Common Stock
2024-02-23	Hale David F	Buy	266	Common Stock
2024-02-23	Hale David F	Buy	714	Common Stock
2024-02-23	Wills Robert James	Sell	980	Common Stock

INSIDER POWER
19.18
Last 100 transactions
Buy: 5 802 851 \| Sell: 3 918 128

Oncternal Therapeutics Correlación

10 Correlaciones Más Positivas

10 Correlaciones Más Negativas

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Oncternal Therapeutics Finanzas

Annual	2023
Ingresos:	$785 000
Beneficio Bruto:	$-28.97M (-3 690.19 %)
EPS:	$-13.43

FY	2023
Ingresos:	$785 000
Beneficio Bruto:	$-28.97M (-3 690.19 %)
EPS:	$-13.43

FY	2022
Ingresos:	$1.49M
Beneficio Bruto:	$1.31M (87.99 %)
EPS:	$-16.50

FY	2021
Ingresos:	$4.32M
Beneficio Bruto:	$4.32M (100.00 %)
EPS:	$-0.640

Financial Reports:

No articles found.

Oncternal Therapeutics

Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins. It is also developing ONCT-808, a chimeric antigen receptor T-cells (CAR-T) product candidate that targets ROR1; and ONCT-534, a dual-action androgen receptor inhibitor product candidate for the treatment of castration-resistant prostate and other androgen receptor-driven cancers. Oncternal Therapeutics, Inc. has license agreements with the Regents of the University of California; Georgetown University; The University of Texas MD Anderson Cancer Center; Shanghai Pharmaceutical (USA) Inc.; and University of Tennessee Research Foundation. Oncternal Therapeutics, Inc. has a research collaboration with Celularity Inc. to evaluate placental derived-cellular therapies targeting ROR1. The company is headquartered in San Diego, California.